alanine has been researched along with Ache in 24 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The non-dopaminergic and dopaminergic actions of safinamide may alleviate pain in patients with Parkinson's disease (PD)." | 9.41 | Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study. ( Hattori, N; Ishida, T; Koebis, M; Kogo, Y; Nomoto, M; Suzuki, I; Tsuboi, Y, 2021) |
| "To investigate the effects of safinamide on pain management in PD patients with motor fluctuations using pooled data from studies 016 and SETTLE." | 9.24 | Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis. ( Barone, P; Bonizzoni, E; Cattaneo, C; Sardina, M, 2017) |
| "Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain." | 8.12 | Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. ( Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M, 2022) |
| "Our results suggest that safinamide may have a beneficial effect on pain, a key unmet need in fluctuating PD patients." | 8.02 | Effects of safinamide on pain in patients with fluctuating Parkinson's disease. ( Falkenburger, B; Grigoriou, S; Hausbrand, D; Leta, V; Martínez-Martín, P; Odin, P; Ray Chaudhuri, K; Reichmann, H; Rukavina, K, 2021) |
| "The effects of the specific 5-HT uptake inhibitors alaproclate and zimelidine, the 5-HT releasing compound p-chloroamphetamine (PCA) and the specific NA uptake inhibitor desipramine on pain sensitivity were examined in male rats using the hot-plate and tail-flick methods." | 7.66 | Test-specific effects of the 5-HT reuptake inhibitors alaproclate and zimelidine on pain sensitivity and morphine analgesia. ( Holm, AC; Ogren, SO, 1980) |
| "Pain is a common and disabling non-motor symptom (NMS) of Parkinson's disease (PD), which occurs through the course of the disease, often unrecognized and undertreated." | 5.56 | Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study. ( Bovi, T; Di Vico, IA; Geroin, C; Segatti, A; Squintani, G; Tinazzi, M, 2020) |
| "The non-dopaminergic and dopaminergic actions of safinamide may alleviate pain in patients with Parkinson's disease (PD)." | 5.41 | Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study. ( Hattori, N; Ishida, T; Koebis, M; Kogo, Y; Nomoto, M; Suzuki, I; Tsuboi, Y, 2021) |
| "To investigate the effects of safinamide on pain management in PD patients with motor fluctuations using pooled data from studies 016 and SETTLE." | 5.24 | Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis. ( Barone, P; Bonizzoni, E; Cattaneo, C; Sardina, M, 2017) |
| "Treatment with levodopa increases pain thresholds in patients with PD." | 5.05 | Current Status of Pain Management in Parkinson's Disease. ( Bruno, V; Farcy, N; Karnik, V; Zamorano, C, 2020) |
| "Safinamide seems to be an effective adjunctive treatment in PD patients treated with bilateral STN-DBS, leading to an improvement of motor complications, mood and pain." | 4.12 | Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. ( Artusi, CA; Balestrino, R; Bonvegna, S; Fabbri, M; Imbalzano, G; Lopiano, L; Mancini, F; Montanaro, E; Rizzone, MG; Romagnolo, A; Zibetti, M, 2022) |
| "Our results suggest that safinamide may have a beneficial effect on pain, a key unmet need in fluctuating PD patients." | 4.02 | Effects of safinamide on pain in patients with fluctuating Parkinson's disease. ( Falkenburger, B; Grigoriou, S; Hausbrand, D; Leta, V; Martínez-Martín, P; Odin, P; Ray Chaudhuri, K; Reichmann, H; Rukavina, K, 2021) |
| " In rats with hindpaw inflammation, inhibitors of aminopeptidase N (APN; bestatin) or neutral endopeptidase (NEP; thiorphan), and a dual inhibitor, NH(2)-CH-Ph-P(O)(OH)CH(2)-CH-CH(2)Ph(p-Ph)-CONH-CH-CH(3)-COOH (P8B), were applied to injured paws." | 3.78 | Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue. ( Fournie-Zaluski, MC; Gore, C; Labuz, D; Machelska, H; Roques, BP; Schreiter, A; Stein, C, 2012) |
| " We show that the conjugate of arachidonic acid and glycine (N-arachidonylglycine (NAGly)) is present in bovine and rat brain as well as other tissues and that it suppresses tonic inflammatory pain." | 3.71 | Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. ( Bisogno, T; Burstein, S; Chang, SY; Coop, A; De Petrocellis, L; Di Marzo, V; Huang, SM; Maeda, DY; Petros, TJ; Sivakumar, R; Walker, JM; Zavitsanos, PA; Zipkin, RE, 2001) |
| "The NMDA receptor and the NK-1 receptor are important determinants of the MAC of isoflurane, exerting this influence by inhibition of pain transmission in the spinal cord, while mGlu and AMPA receptors have no effect on the MAC of isoflurane." | 3.70 | Intrathecal co-administration of NMDA antagonist and NK-1 antagonist reduces MAC of isoflurane in rats. ( Goto, F; Ishizaki, K; Karasawa, S; Nara, T; Obata, H; Sasaki, M, 1999) |
| "The effects of the specific 5-HT uptake inhibitors alaproclate and zimelidine, the 5-HT releasing compound p-chloroamphetamine (PCA) and the specific NA uptake inhibitor desipramine on pain sensitivity were examined in male rats using the hot-plate and tail-flick methods." | 3.66 | Test-specific effects of the 5-HT reuptake inhibitors alaproclate and zimelidine on pain sensitivity and morphine analgesia. ( Holm, AC; Ogren, SO, 1980) |
| "Safinamide is an important adjunct to standard parkinsonian medication for alleviating pain in PD." | 2.58 | Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis. ( Akhter, S; Malik, SH; Qureshi, AR; Rana, AQ; Rana, R; Rizvi, SFH; Sarfraz, Z; Vannabouathong, C, 2018) |
| "Neonatal pain is often undertreated." | 2.50 | [Maybe it hurts more than we think! Neonatal pain]. ( Mikos, B, 2014) |
| "Pain is a common and disabling non-motor symptom (NMS) of Parkinson's disease (PD), which occurs through the course of the disease, often unrecognized and undertreated." | 1.56 | Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study. ( Bovi, T; Di Vico, IA; Geroin, C; Segatti, A; Squintani, G; Tinazzi, M, 2020) |
| "Strychnine induced two types of motor seizures: (1) falling over with tail whipping and (2) convulsions." | 1.27 | Prevention of the convulsant and hyperalgesic action of strychnine by intrathecal glycine and related amino acids. ( Banas, C; Beyer, C; Gomora, P; Komisaruk, BR, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grigoriou, S | 1 |
| Martínez-Martín, P | 1 |
| Ray Chaudhuri, K | 1 |
| Rukavina, K | 1 |
| Leta, V | 1 |
| Hausbrand, D | 1 |
| Falkenburger, B | 1 |
| Odin, P | 1 |
| Reichmann, H | 1 |
| Tsuboi, Y | 1 |
| Koebis, M | 1 |
| Kogo, Y | 1 |
| Ishida, T | 1 |
| Suzuki, I | 1 |
| Nomoto, M | 1 |
| Hattori, N | 1 |
| Rizzone, MG | 1 |
| Mancini, F | 1 |
| Artusi, CA | 1 |
| Balestrino, R | 1 |
| Bonvegna, S | 1 |
| Fabbri, M | 1 |
| Imbalzano, G | 1 |
| Montanaro, E | 1 |
| Romagnolo, A | 1 |
| Zibetti, M | 1 |
| Lopiano, L | 1 |
| De Masi, C | 1 |
| Liguori, C | 1 |
| Spanetta, M | 1 |
| Fernandes, M | 1 |
| Cerroni, R | 1 |
| Garasto, E | 1 |
| Pierantozzi, M | 1 |
| Mercuri, NB | 1 |
| Stefani, A | 1 |
| Karnik, V | 1 |
| Farcy, N | 1 |
| Zamorano, C | 1 |
| Bruno, V | 1 |
| Geroin, C | 1 |
| Di Vico, IA | 1 |
| Squintani, G | 1 |
| Segatti, A | 1 |
| Bovi, T | 1 |
| Tinazzi, M | 1 |
| Qureshi, AR | 1 |
| Rana, AQ | 1 |
| Malik, SH | 1 |
| Rizvi, SFH | 1 |
| Akhter, S | 1 |
| Vannabouathong, C | 1 |
| Sarfraz, Z | 1 |
| Rana, R | 1 |
| Mikos, B | 1 |
| Cattaneo, C | 1 |
| Barone, P | 1 |
| Bonizzoni, E | 1 |
| Sardina, M | 1 |
| Salomé, C | 1 |
| Salomé-Grosjean, E | 1 |
| Stables, JP | 1 |
| Kohn, H | 1 |
| Moon, SJ | 2 |
| Woo, YJ | 1 |
| Jeong, JH | 2 |
| Park, MK | 2 |
| Oh, HJ | 1 |
| Park, JS | 2 |
| Kim, EK | 2 |
| Cho, ML | 2 |
| Park, SH | 2 |
| Kim, HY | 2 |
| Min, JK | 2 |
| Schreiter, A | 1 |
| Gore, C | 1 |
| Labuz, D | 1 |
| Fournie-Zaluski, MC | 2 |
| Roques, BP | 2 |
| Stein, C | 1 |
| Machelska, H | 1 |
| Yang, EJ | 1 |
| Li, W | 1 |
| Neugebauer, V | 2 |
| Yoshimura, M | 1 |
| Yonehara, N | 1 |
| Liu, T | 1 |
| Pang, XY | 1 |
| Bai, ZT | 1 |
| Chai, ZF | 1 |
| Jiang, F | 1 |
| Ji, YH | 1 |
| Ogren, SO | 1 |
| Holm, AC | 1 |
| Cuthbertson, DP | 1 |
| Lücke, T | 1 |
| Schaible, HG | 1 |
| Young, MR | 1 |
| Fleetwood-Walker, SM | 1 |
| Dickinson, T | 1 |
| Blackburn-Munro, G | 1 |
| Sparrow, H | 1 |
| Birch, PJ | 1 |
| Bountra, C | 1 |
| Noble, F | 1 |
| Smadja, C | 1 |
| Valverde, O | 1 |
| Maldonado, R | 1 |
| Coric, P | 1 |
| Turcaud, S | 1 |
| Ishizaki, K | 1 |
| Sasaki, M | 1 |
| Karasawa, S | 1 |
| Obata, H | 1 |
| Nara, T | 1 |
| Goto, F | 1 |
| Huang, SM | 1 |
| Bisogno, T | 1 |
| Petros, TJ | 1 |
| Chang, SY | 1 |
| Zavitsanos, PA | 1 |
| Zipkin, RE | 1 |
| Sivakumar, R | 1 |
| Coop, A | 1 |
| Maeda, DY | 1 |
| De Petrocellis, L | 1 |
| Burstein, S | 1 |
| Di Marzo, V | 1 |
| Walker, JM | 1 |
| Beyer, C | 1 |
| Banas, C | 1 |
| Gomora, P | 1 |
| Komisaruk, BR | 1 |
4 reviews available for alanine and Ache
| Article | Year |
|---|---|
Current Status of Pain Management in Parkinson's Disease.
Topics: Acetylcholine Release Inhibitors; Alanine; Analgesics; Antiparkinson Agents; Apomorphine; Benzylamin | 2020 |
Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Topics: Alanine; Analgesics; Benzylamines; Electric Stimulation Therapy; Humans; Pain; Pain Management; Park | 2018 |
[Maybe it hurts more than we think! Neonatal pain].
Topics: Alanine; Animals; Blood Pressure; Fetus; Heart Rate; Humans; Infant, Newborn; Infant, Premature; Lac | 2014 |
Alterations in metabolism following injury: part II.
Topics: Alanine; Amino Acids; Amino Acids, Branched-Chain; Animals; Carbohydrate Metabolism; Endocrine Gland | 1980 |
2 trials available for alanine and Ache
| Article | Year |
|---|---|
Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Japan; Levodopa; Pain; Parkinson Disease | 2021 |
Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis.
Topics: Adult; Aged; Alanine; Benzylamines; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome | 2017 |
18 other studies available for alanine and Ache
| Article | Year |
|---|---|
Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Pain; Parkinson Disease; Pilot Projects; Qualit | 2021 |
Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
Topics: Alanine; Benzylamines; Deep Brain Stimulation; Dyskinesias; Humans; Levodopa; Pain; Parkinson Diseas | 2022 |
Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study.
Topics: Alanine; Benzylamines; Fatigue; Female; Humans; Male; Pain; Parkinson Disease; Quality of Life | 2022 |
Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study.
Topics: Alanine; Antiparkinson Agents; Benzylamines; Humans; Pain; Parkinson Disease; Quality of Life | 2020 |
Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.
Topics: Acetamides; Alanine; Amides; Amino Acids; Animals; Anticonvulsants; Benzylamines; Drug Evaluation, P | 2010 |
Rebamipide attenuates pain severity and cartilage degeneration in a rat model of osteoarthritis by downregulating oxidative damage and catabolic activity in chondrocytes.
Topics: Alanine; Analgesics; Animals; Arthritis, Experimental; Biomarkers; Cartilage, Articular; Cells, Cult | 2012 |
Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue.
Topics: Alanine; Amino Acid Sequence; Animals; Antibodies; CD13 Antigens; Dose-Response Relationship, Drug; | 2012 |
Augmented chondroprotective effect of coadministration of celecoxib and rebamipide in the monosodium iodoacetate rat model of osteoarthritis.
Topics: Administration, Oral; Alanine; Animals; Arthritis, Experimental; Behavior, Animal; Cartilage; Celeco | 2013 |
Differential changes of group II and group III mGluR function in central amygdala neurons in a model of arthritic pain.
Topics: Alanine; Aminobutyrates; Amygdala; Animals; Arthritis; Bridged Bicyclo Compounds; Disease Models, An | 2006 |
Alteration in sensitivity of ionotropic glutamate receptors and tachykinin receptors in spinal cord contribute to development and maintenance of nerve injury-evoked neuropathic pain.
Topics: Alanine; Analgesics; Animals; Behavior, Animal; Benzamides; Dizocilpine Maleate; Excitatory Amino Ac | 2006 |
Intrathecal injection of glutamate receptor antagonists/agonist selectively attenuated rat pain-related behaviors induced by the venom of scorpion Buthus martensi Karsch.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Alanine; Animals; Dizocilpine Maleate; Excitatory Amino Acid A | 2007 |
Test-specific effects of the 5-HT reuptake inhibitors alaproclate and zimelidine on pain sensitivity and morphine analgesia.
Topics: Alanine; Analgesia; Animals; Behavior, Animal; Brompheniramine; Desipramine; Dose-Response Relations | 1980 |
Requirement of metabotropic glutamate receptors for the generation of inflammation-evoked hyperexcitability in rat spinal cord neurons.
Topics: Acute Disease; Afferent Pathways; Alanine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; | 1994 |
Behavioural and electrophysiological evidence supporting a role for group I metabotropic glutamate receptors in the mediation of nociceptive inputs to the rat spinal cord.
Topics: Alanine; Animals; Antihypertensive Agents; Behavior, Animal; Benzothiadiazines; Cycloleucine; Electr | 1997 |
Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 120.
Topics: Administration, Oral; Alanine; Animals; Disulfides; Dose-Response Relationship, Drug; Electric Stimu | 1997 |
Intrathecal co-administration of NMDA antagonist and NK-1 antagonist reduces MAC of isoflurane in rats.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Alanine; Anesthetics, Inhalation; Animals; Biphenyl Compounds; | 1999 |
Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain.
Topics: Alanine; Amidohydrolases; Amino Acids; Animals; Arachidonic Acid; Arachidonic Acids; Brain; Calcium; | 2001 |
Prevention of the convulsant and hyperalgesic action of strychnine by intrathecal glycine and related amino acids.
Topics: Alanine; Amino Acids; Animals; Betaine; Glycine; Injections, Spinal; Pain; Rats; Rats, Inbred Strain | 1988 |